A disease progression model estimating the benefit of tolvaptan on time to end-stage renal disease for patients with rapidly progressing autosomal dominant polycystic kidney disease

A disease progression model estimating the benefit of tolvaptan on time to end-stage renal disease for patients with rapidly progressing autosomal dominant polycystic kidney disease

Abstract Background Tolvaptan was approved in the United States in 2018 for patients with autosomal dominant polycystic kidney disease (ADPKD) at risk of rapid progression as assessed in a 3-year phase 3 clinical trial (TEMPO 3:4). An extension study (TEMPO 4:4) showed continued delay in progression...

Full description

Bibliographic Details
Main Authors: Gregory Mader, Deirdre Mladsi, Myrlene Sanon, Molly Purser, Christine L. Barnett, Dorothee Oberdhan, Terry Watnick, Stephen Seliger
Format: Article
Language:English
Published: BMC 2022-10-01
Series:BMC Nephrology
Subjects:
Autosomal dominant polycystic kidney disease
Disease modeling
End-stage renal disease
Renal function decline
Tolvaptan
Online Access:https://doi.org/10.1186/s12882-022-02956-8

Internet

https://doi.org/10.1186/s12882-022-02956-8

Similar Items